Isabelle Hardy completed her medical degree and residency at the University of Montreal. She then pursued two years of fellowship in oculoplastic surgery at McGill University and at the Rothschild Foundation Hospital in Paris, France.

Upon returning to the University of Montreal, she actively promoted oculoplastic surgery. Under her leadership, the oculoplastic division was created, and the surgical team expanded from 3 to over 10 professors of oculoplastic, with more than 20 international fellows in oculoplastic surgery having been trained.

She served as Chief of the University Eye Center at Maisonneuve-Rosemont Hospital and later as Department Chair from 2012 to 2024, strongly supporting the advancement of research and faculty development.

Isabelle established a TED research program and participated in over 10 clinical trials on TED. She recently formed a multidisciplinary board at her hospital to manage complex patients with TED. She has published more than 30 papers and spoken at numerous international meetings. In 2024, she received the Leadership Award from the Rector of the University of Montreal.

Financial disclosure: Dr. Hardy has/had an affiliation (financial or otherwise) with a commercial organization.

1. Amgen
2. Roche
3. Horizon-Amgen
4. Sling Therapeutic 
5. Immunovant